Literature DB >> 26195205

The Role of Sarcopenia and Frailty in Hepatic Encephalopathy Management.

Catherine Lucero1, Elizabeth C Verna2.   

Abstract

Normal regulation of total body and circulating ammonia requires a delicate interplay in ammonia formation and breakdown between several organ systems. In the setting of cirrhosis and portal hypertension, the decreased hepatic clearance of ammonia leads to significant dependence on skeletal muscle for ammonia detoxification; however, cirrhosis is also associated with muscle depletion and decreased functional muscle mass. Thus, patients with diminished muscle mass and sarcopenia may have a decreased ability to compensate for hepatic insufficiency and a higher likelihood of developing physiologically significant hyperammonemia and hepatic encephalopathy.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Frailty; Hepatic encephalopathy; Sarcopenia

Mesh:

Substances:

Year:  2015        PMID: 26195205     DOI: 10.1016/j.cld.2015.04.003

Source DB:  PubMed          Journal:  Clin Liver Dis        ISSN: 1089-3261            Impact factor:   6.126


  11 in total

1.  Myosteatosis and sarcopenia are associated with hepatic encephalopathy in patients with cirrhosis.

Authors:  Rahima A Bhanji; Carlos Moctezuma-Velazquez; Andres Duarte-Rojo; Maryam Ebadi; Sunita Ghosh; Christopher Rose; Aldo J Montano-Loza
Journal:  Hepatol Int       Date:  2018-06-07       Impact factor: 6.047

Review 2.  Nutrition and Muscle in Cirrhosis.

Authors:  Anil C Anand
Journal:  J Clin Exp Hepatol       Date:  2017-11-08

3.  Functional Status at Liver Transplant Waitlisting Correlates With Greater Odds of Encephalopathy, Ascites, and Spontaneous Bacterial Peritonitis.

Authors:  Patrick McCabe; Grishma Hirode; Robert Wong
Journal:  J Clin Exp Hepatol       Date:  2020-04-27

4.  A Comparison of Different Frailty Scores and Impact of Frailty on Outcome in Patients With Cirrhosis.

Authors:  Surender Singh; Sunil Taneja; Puneeta Tandon; Akash Bansal; Ujjwal Gorsi; Akash Roy; Arka De; Nipun Verma; Madhumita Premkumar; Ajay Duseja; Radha K Dhiman; Virendra Singh
Journal:  J Clin Exp Hepatol       Date:  2021-07-21

5.  The improvement in body composition including subcutaneous and visceral fat reduces ammonia and hepatic encephalopathy after transjugular intrahepatic portosystemic shunt.

Authors:  Stefania Gioia; Lorenzo Ridola; Ludovica Cristofaro; Manuela Merli; Jessica Faccioli; Oliviero Riggio; Silvia Nardelli
Journal:  Liver Int       Date:  2021-09-28       Impact factor: 8.754

6.  Frailty as Tested by Gait Speed is an Independent Risk Factor for Cirrhosis Complications that Require Hospitalization.

Authors:  Michael A Dunn; Deborah A Josbeno; Amit D Tevar; Vikrant Rachakonda; Swaytha R Ganesh; Amy R Schmotzer; Elizabeth A Kallenborn; Jaideep Behari; Douglas P Landsittel; Andrea F DiMartini; Anthony Delitto
Journal:  Am J Gastroenterol       Date:  2016-08-30       Impact factor: 10.864

7.  Effects of an Exercise Programme on Functional Capacity, Body Composition and Risk of Falls in Patients with Cirrhosis: A Randomized Clinical Trial.

Authors:  Eva Román; Cristina García-Galcerán; Teresa Torrades; Silvia Herrera; Ana Marín; Maite Doñate; Edilmar Alvarado-Tapias; Jorge Malouf; Laura Nácher; Ricard Serra-Grima; Carlos Guarner; Juan Cordoba; German Soriano
Journal:  PLoS One       Date:  2016-03-24       Impact factor: 3.240

Review 8.  Sarcopenia: Ammonia metabolism and hepatic encephalopathy.

Authors:  Ankur Jindal; Rakesh Kumar Jagdish
Journal:  Clin Mol Hepatol       Date:  2019-04-22

9.  KASL clinical practice guidelines for liver cirrhosis: Varices, hepatic encephalopathy, and related complications.

Authors: 
Journal:  Clin Mol Hepatol       Date:  2020-01-10

10.  Loss of skeletal muscle mass affects the incidence of minimal hepatic encephalopathy: a case control study.

Authors:  Masakuni Tateyama; Hideaki Naoe; Motohiko Tanaka; Kentaro Tanaka; Satoshi Narahara; Takayuki Tokunaga; Takeshi Kawasaki; Yoko Yoshimaru; Katsuya Nagaoka; Takehisa Watanabe; Hiroko Setoyama; Yutaka Sasaki; Yasuhito Tanaka
Journal:  BMC Gastroenterol       Date:  2020-11-09       Impact factor: 3.067

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.